Meta-analysis of the Related Nutritional Supplements Dimethyl Sulfoxide and Methylsulfonylmethane in the Treatment of Osteoarthr

Primary tabs

field_vote: 
Average: 7 (1 vote)
Publication type: 
Therapeutic Substance(s): 
Disease(s): 

Evid Based Complement Alternat Med. 2009 May 27.

Meta-analysis
of the Related Nutritional Supplements Dimethyl Sulfoxide and
Methylsulfonylmethane in the Treatment of Osteoarthritis of the Knee.

 
Brien S, Prescott P, Lewith G.
Aldermoor Health Centre, Aldermoor Close, Southampton, Hampshire, SO16 5ST, UK.

.
Dimethyl
sulphoxide and methylsulfonylmethane are two related nutritional
supplements used for symptomatic relief of osteoarthritis (OA). We
conducted a meta-analysis to evaluate their efficacy in reducing pain
associated with OA. Randomized or quasi-randomized controlled trials
(RCTs), identified by systematic electronic searches, citation tracking
and searches of clinical trial registries, assessing these supplements
in osteoarthritis of any joint were considered for inclusion.
Meta-analysis, based on difference in mean pain related outcomes
between treatment and comparator groups, was carried out based on a
random effect model. Seven potential trials were identified of which
three RCTs, two DMSO and one MSM (total N = 326 patients) were eligible
for inclusion. All three trials were considered high methodological
quality. A significant degree of heterogeneity (chi(2) = 6.28, P =
0.043) was revealed. Two studies demonstrated statistically significant
(but not clinically relevant) reduction in pain compared with controls;
with one showing no group difference. The meta-analysis confirmed a non
significant reduction of pain on visual analogue scale of 6.34 mm (SE =
3.49, 95% CI, -0.49, 13.17). The overall effect size of 1.82 was
neither statistically nor clinically significant. Current evidence
suggests DMSO and MSM are not clinically effective in the reduction of
pain in the treatment of OA. No definitive conclusions can currently be
drawn from the data due to the mixed findings and the use of inadequate
dosing periods.